Article Text

Download PDFPDF

Correspondence on ‘NCF1-339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in systemic lupus erythematosus’ by Linge et al
Free
  1. George N Goulielmos1,2,
  2. Maria I Zervou1,
  3. Elias Eliopoulos3
  1. 1Section of Molecular Pathology and Human Genetics, Department of Internal Medicine, School of Medicine, University of Crete, Heraklion, Greece
  2. 2Department of Internal Medicine, University Hospital of Heraklion, Heraklion, Greece
  3. 3Laboratory of Genetics, Department of Biotechnology, Agricultural University of Athens, Athens, Greece
  1. Correspondence to Dr George N Goulielmos, Section of Molecular Pathology and Human Genetics, Department of Internal Medicine, School of Medicine, University of Crete, Heraklion 74100, Greece; goulielmos{at}med.uoc.gr

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with great interest the article by Linge et al1 on ‘NCF1- 339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in systemic lupus erythematosus’1 as well as the response of Linge and Bengtsson2 to the comment by Joob and Wiwanitkit,3 who raised a question regarding the importance and the role of the NCF1-339 rs201802880 (p. Arg90His) polymorphism in systemic lupus erythematosus (SLE). Linge and Bengtsson3 nicely placed this polymorphism in a functional context, pointing out that the amino acid shift from arginine to histidine at a PX domain of the NCF1 protein (a domain of crucial importance in the membrane binding4 reduces reactive oxygen species (ROS) response.5 Of note, the rs201802880 p. Arg90His variant of he NCF1 gene has been associated, apart from SLE, with rheumatoid arthritis and Sjögren’s syndrome in adult patients6 as well as with early-onset interferonopathy in paediatric patients.7

Our aim with this letter was to extend the information given by Linge and Bengtsson3 by presenting data that elucidate further the significance of the rs201802880 Arg90His variant from another viewpoint, using data from a structural biology approach, thus analysing this variant in the various genetically controlled functions that is involved, including the neutrophil extracellular trap formation, the reduced extracellular ROS production in neutrophils and the decreased NADPH oxidase function.1 To this end, we have recently evaluated the structural significance of the rs201802880 variant on the p47phox PX domain of the NCF1 protein by constructing a three-dimensional structural model, focusing on the phosphate-binding pocket of NCF1 p47phox domain with the electrostatic molecular surface.8 Our molecular investigation showed that in this variant, the functionality of the p47phox PX cytosolic subunit of neutrophil NADPH oxidase has been modified, leading to affinity reduction to PtdIns(3,4)P2 caused by the loss of specific phosphoinositide head group interactions and affecting the p47phox translocation to the plasma membrane.

The structural biological information reported here may help the interpretation of the findings of Linge et al1 from the structural–functional point of view and, apparently, is in agreement with the statements in the comment of Linge and Bengtsson3 that emphasise on the crucial importance of the NCF1- 339 polymorphism under discussion.

Ethics statements

Patient consent for publication

References

Footnotes

  • Handling editor Josef S Smolen

  • Contributors GNG, MIZ and EE prepared the manuscript and approved the final version.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

  • Provenance and peer review Commissioned; internally peer reviewed.